Handelsavisen
prelaunch
Companies Healthcare 102460.KS
10
102460.KS KRX Pharmaceuticals

102460.Ks

$9 910,00
Open in Charts → Attach watcher ⌖
KRW
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
181,8B KRW
P/E
EV / Rev
Div yield
0,00 %
Op margin
-20,7 %
ROE
-13,5 %
Net margin
-20,3 %
Debt / equity
0,98
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of prescription drugs and related healthcare products.

Business. The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of prescription drugs and related healthcare products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-13,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 102460.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 102460.KS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of prescription drugs and related healthcare products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a debt-to-equity ratio of 0.98, indicating a relatively balanced mix of debt and equity financing. However, the company's liquidity position is constrained, with a current ratio of 0.56, suggesting that it may struggle to meet short-term obligations without additional financing. The company's price-to-book ratio of 0.97 and price-to-tangible-book ratio of 0.97 indicate that the market values the company's equity at a slight discount to its book value.

    Profitability metrics reveal a challenging operating environment for the company. The company reported a net loss of 29,633,118,380 KRW, with a return on equity of -13.45% and a return on assets of -6.37%. These figures are significantly below the industry median for profitability, indicating that the company is underperforming relative to its peers in terms of generating returns on invested capital and assets.

    The company's revenue is primarily concentrated in a single geographic region, with no disclosed segment breakdown. This lack of diversification increases the company's exposure to regional economic and regulatory risks. The absence of detailed segment data limits the ability to assess the performance of different product lines or geographic markets.

    The company's growth trajectory is mixed. While it reported a revenue of 145,928,626,140 KRW, the net loss and negative operating income suggest that the company is not currently generating sustainable earnings. The outlook for the current fiscal year indicates a continuation of this trend, with no significant improvement in revenue or profitability expected in the near term.

    Risk factors for the company include its high debt load and negative net cash position, which could limit its ability to invest in growth opportunities or withstand economic downturns. The company's liquidity risk is rated as medium, and its dilution risk is low, indicating that while it may need to raise additional capital, it is not currently facing significant pressure to issue new shares.

    Recent events, including the company's latest financial filing, show a continued focus on managing cash flow and reducing debt. The company's operating cash flow of 1,456,689,950 KRW is insufficient to cover its capital expenditures of 7,915,547,610 KRW, leading to a negative free cash flow of 5,754,212,990 KRW. This suggests that the company is investing heavily in its operations but is not generating enough cash to sustain these investments without external financing.

    Key takeaways
    • The company is operating at a net loss with a negative return on equity and assets, indicating poor profitability.
    • The company's liquidity position is weak, with a current ratio of 0.56 and a negative net cash position.
    • The company's revenue is concentrated in a single geographic region, increasing its exposure to regional risks.
    • The company is investing in capital expenditures but is not generating sufficient free cash flow to sustain these investments.
    • The company's debt-to-equity ratio is balanced, but its high debt load and negative net cash position pose liquidity risks.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $9 910,00
    Market cap
    $214.04B
    Enterprise value
    $423.50B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    290.7x
    P / B
    1.0x
    P / Tangible book
    1.0x
    Tangible book
    $220.27B
    Net cash
    -$209.46B
    Current ratio
    0.6
    Debt / equity
    1.0
    ROA
    -6.4%
    ROE
    -13.5%
    Cash conversion
    -5.0%
    CapEx / revenue
    -5.4%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-20,7 %Bottom quartile
    Net Margin-20,3 %Bottom quartile
    ROE-13,5 %Bottom quartile
    Capex / Rev-5,4 %Below median
    D/E0,98Bottom quartile
    Cash Conv-0,05Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • 102460.KS Market data — financials · 2026-05-26
    • Reyon Pharmaceutical Co Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    102460.KSCanonical
    KRX · KRW

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage